Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
Metrics: PDF 1281 views | HTML 1305 views | ?
Xiuli Feng1,2,*, Yan Zhang1,3,*, Tao Li1 and Yu Li1
1Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
2Department of Respiratory Medicine, People’s Hospital of Qingzhou, Weifang, Shandong 262500, China
3The Fourth People’s Hospital of Jinan, Jinan, Shandong 250031, China
*These authors have contributed equally to this work
Yu Li, email: firstname.lastname@example.org
Keywords: lung adenocarcinoma; sequence; chemotherapy
Received: April 20, 2017 Accepted: October 03, 2017 Published: December 14, 2017
Combination of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved to be a potent anti-drug for the treatment of tumors. However, survival time was not extended for the patients with lung adenocarcinoma (AdC) compared with first-line chemotherapy. In the present study, we attempt to assess the optimal schedule of the combined administration of pemetrexed and icotinib/erlotinib in AdC cell lines. Human lung AdC cell lines with wild-type (A549), EGFR T790M (H1975) and activating EGFR mutation (HCC827) were applied in vitro to assess the differential efficacy of various sequential regimens on cell viability, cell apoptosis and cell cycle distribution. The results suggested that the antiproliferative effect of the sequence of pemetrexed followed by icotinib/erlotinib was more effective than that of icotinib/erlotinib followed by pemetrexed. Additionally, a reduction of G1 phase and increased S phase in sequence of pemetrexed followed by icotinib/erlotinib was also observed, promoting cell apoptosis. Thus, the sequential administration of pemetrexed followed by icotinib/erlotinib exerted a synergistic effect on HCC827 and H1975 cell lines compared with the reverse sequence. The sequential treatment of pemetrexed followed by icotinib/erlotinib has been demonstrated promising results. This treatment strategy warrants further confirmation in patients with advanced lung AdC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.